MX2018000052A - Composiciones y métodos para la terapia combinada con virus del dengue y celulas dendríticas. - Google Patents
Composiciones y métodos para la terapia combinada con virus del dengue y celulas dendríticas.Info
- Publication number
- MX2018000052A MX2018000052A MX2018000052A MX2018000052A MX2018000052A MX 2018000052 A MX2018000052 A MX 2018000052A MX 2018000052 A MX2018000052 A MX 2018000052A MX 2018000052 A MX2018000052 A MX 2018000052A MX 2018000052 A MX2018000052 A MX 2018000052A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- dendritic cells
- dengue virus
- cancer
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 241000725619 Dengue virus Species 0.000 title abstract 2
- 210000004443 dendritic cell Anatomy 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 5
- 201000011510 cancer Diseases 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000005787 hematologic cancer Diseases 0.000 abstract 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
En la presente invención se describen composiciones y métodos para tratar el cáncer mediante la combinación de células dendríticas pulsadas con antígeno tumoral y virus del dengue. La combinación de las dos formas de intervención terapéutica proporciona una mayor reducción de las células cancerígenas, en comparación con la aplicación de los dos métodos por separado. El cáncer objetivo de las composiciones y métodos descritos en la presente invención, puede ser un cáncer sólido o un cáncer de sangre.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562231351P | 2015-07-02 | 2015-07-02 | |
PCT/US2016/040787 WO2017004567A1 (en) | 2015-07-02 | 2016-07-01 | Compositions and methods for combination therapy with dengue virus and dendritic cells |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018000052A true MX2018000052A (es) | 2018-05-11 |
Family
ID=57609586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018000052A MX2018000052A (es) | 2015-07-02 | 2016-07-01 | Composiciones y métodos para la terapia combinada con virus del dengue y celulas dendríticas. |
Country Status (8)
Country | Link |
---|---|
US (6) | US9730989B2 (es) |
EP (1) | EP3316897A4 (es) |
JP (2) | JP2018522880A (es) |
CN (1) | CN107921063A (es) |
CA (1) | CA2991212A1 (es) |
DE (1) | DE202016008300U1 (es) |
MX (1) | MX2018000052A (es) |
WO (1) | WO2017004567A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3316897A4 (en) | 2015-07-02 | 2019-03-13 | Primevax Immuno-Oncology, Inc. | COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS |
CA2999881A1 (en) * | 2015-09-26 | 2017-03-30 | PrimeVax Immuno-Oncology, Inc. | Compositions and methods for producing dendritic cells |
WO2018093907A1 (en) | 2016-11-16 | 2018-05-24 | PrimeVax Immuno-Oncology, Inc. | Combination immunotherapies for treatment of cancer |
CA3049225A1 (en) * | 2017-01-04 | 2018-07-12 | PrimeVax Immuno-Oncology, Inc. | Compositions and methods for therapy with dengue virus |
EP3638304A4 (en) * | 2017-06-12 | 2021-02-24 | Washington University | CICAVIRUS STRAINS FOR TREATMENT OF GLIOBLASTOMES |
SG11201912163WA (en) * | 2017-06-15 | 2020-01-30 | Primevax Immuno Oncology Inc | Compositions and methods for cancer therapy with dengue virus and dendritic cells |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1015972A (en) | 1905-09-25 | 1912-01-30 | Westinghouse Electric & Mfg Co | Electric switch. |
US1035755A (en) | 1908-07-21 | 1912-08-13 | Glenn S Smith | Draftsman's apparatus. |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
EP1056834A2 (en) * | 1998-02-20 | 2000-12-06 | The Rockefeller University | Apoptotic cell-mediated antigen presentation to dendritic cells |
US6524587B1 (en) * | 1998-05-05 | 2003-02-25 | Bruce W. Lyday | Hyperthermia and immunotherapy for leukemias lymphomas, and solid tumors |
US6048686A (en) | 1998-05-05 | 2000-04-11 | Randy Kyle Brown | Hyperthermia and immunotherapy for cancer |
KR100721745B1 (ko) | 1999-03-26 | 2007-05-25 | 왈터 리드 아미 인스티튜트 오브 리써치 | 다가 뎅기 바이러스 백신 |
AU4040200A (en) * | 1999-03-26 | 2000-10-16 | Walter Reed Army Institute Of Research | Attenuated dengue-2 virus vaccine |
CA2367590A1 (en) | 1999-03-31 | 2000-10-05 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | In vitro induction of antigen-specific t-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens |
EP1484064A1 (en) | 2003-06-04 | 2004-12-08 | Gesellschaft für Biotechnologische Forschung | Therapeutical composition containing dentritic cells and use thereof |
CN101006172B (zh) * | 2004-06-24 | 2012-09-05 | 株式会社载体研究所 | 包含导入了rna病毒的树突状细胞的抗癌剂 |
US8513008B2 (en) | 2004-10-07 | 2013-08-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
KR20170086700A (ko) * | 2005-04-08 | 2017-07-26 | 아르고스 쎄라퓨틱스 인코포레이티드 | 수지상 세포 조성물 및 방법 |
PL2589602T3 (pl) | 2006-08-15 | 2016-11-30 | Rozwinięcie komponentów szczepionki przeciwko wirusowi dengi | |
US8097256B2 (en) * | 2006-09-28 | 2012-01-17 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
BR112012023285A2 (pt) | 2010-03-15 | 2018-12-11 | Univ Pennsylvania | métodos para gerar células dendríticas carregadas de antígeno e para eliciar uma resposta imune em um mamífero, e, composição preservável |
CA2837145A1 (en) | 2011-05-26 | 2012-11-29 | Glaxosmithkline Biologicals Sa | Inactivated dengue virus vaccine |
EP2543386A1 (en) * | 2011-07-05 | 2013-01-09 | Sotio a.s. | Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure |
WO2013154778A1 (en) | 2012-04-11 | 2013-10-17 | Dana-Farber Cancer Institute, Inc. | Host targeted inhibitors of dengue virus and other viruses |
TW201402143A (zh) * | 2012-06-10 | 2014-01-16 | Inviragen Inc | 抗登革熱病毒疫苗之組成物及投藥方法 |
CA2939093A1 (en) | 2014-02-14 | 2015-08-20 | Immune Design Corp. | Immunotherapy of cancer through combination of local and systemic immune stimulation |
US20180127717A1 (en) | 2015-05-07 | 2018-05-10 | Baylor College Of Medicine | Dendritic cell immunotherapy |
EP3316897A4 (en) | 2015-07-02 | 2019-03-13 | Primevax Immuno-Oncology, Inc. | COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS |
CA2999881A1 (en) | 2015-09-26 | 2017-03-30 | PrimeVax Immuno-Oncology, Inc. | Compositions and methods for producing dendritic cells |
WO2018093907A1 (en) | 2016-11-16 | 2018-05-24 | PrimeVax Immuno-Oncology, Inc. | Combination immunotherapies for treatment of cancer |
CA3049225A1 (en) | 2017-01-04 | 2018-07-12 | PrimeVax Immuno-Oncology, Inc. | Compositions and methods for therapy with dengue virus |
SG11201912163WA (en) | 2017-06-15 | 2020-01-30 | Primevax Immuno Oncology Inc | Compositions and methods for cancer therapy with dengue virus and dendritic cells |
-
2016
- 2016-07-01 EP EP16818917.3A patent/EP3316897A4/en not_active Withdrawn
- 2016-07-01 WO PCT/US2016/040787 patent/WO2017004567A1/en active Application Filing
- 2016-07-01 MX MX2018000052A patent/MX2018000052A/es unknown
- 2016-07-01 DE DE202016008300.8U patent/DE202016008300U1/de active Active
- 2016-07-01 CA CA2991212A patent/CA2991212A1/en not_active Abandoned
- 2016-07-01 CN CN201680050897.6A patent/CN107921063A/zh active Pending
- 2016-07-01 US US15/200,751 patent/US9730989B2/en active Active
- 2016-07-01 JP JP2017568234A patent/JP2018522880A/ja active Pending
-
2017
- 2017-06-30 US US15/639,632 patent/US9849167B2/en active Active
- 2017-10-31 US US15/799,793 patent/US10159727B2/en active Active
-
2018
- 2018-10-26 US US16/172,487 patent/US10357553B2/en not_active Expired - Fee Related
-
2019
- 2019-04-19 US US16/389,445 patent/US10946080B2/en active Active
-
2021
- 2021-02-02 US US17/165,270 patent/US20210187086A1/en not_active Abandoned
- 2021-07-08 JP JP2021113634A patent/JP2021176862A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DE202016008300U1 (de) | 2017-07-14 |
US9849167B2 (en) | 2017-12-26 |
US20190046622A1 (en) | 2019-02-14 |
US9730989B2 (en) | 2017-08-15 |
US20210187086A1 (en) | 2021-06-24 |
EP3316897A4 (en) | 2019-03-13 |
US20190247479A1 (en) | 2019-08-15 |
CN107921063A (zh) | 2018-04-17 |
JP2021176862A (ja) | 2021-11-11 |
US10159727B2 (en) | 2018-12-25 |
US20170000868A1 (en) | 2017-01-05 |
US10946080B2 (en) | 2021-03-16 |
US20180050098A1 (en) | 2018-02-22 |
JP2018522880A (ja) | 2018-08-16 |
US10357553B2 (en) | 2019-07-23 |
US20170304422A1 (en) | 2017-10-26 |
CA2991212A1 (en) | 2017-01-05 |
WO2017004567A1 (en) | 2017-01-05 |
EP3316897A1 (en) | 2018-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018000052A (es) | Composiciones y métodos para la terapia combinada con virus del dengue y celulas dendríticas. | |
MX2020010194A (es) | Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activacion de celulas estrelladas hepaticas. | |
EA201691866A1 (ru) | Проникающие в опухоль лимфоциты для адоптивной клеточной терапии | |
MX2021014709A (es) | Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes. | |
MX366804B (es) | Translocaciones de la r-espondina y sus metodos de uso. | |
NZ749218A (en) | Androgen receptor modulator and uses thereof | |
EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
MX363243B (es) | Composiciones para tratar cáncer y usos de dichas composiciones. | |
MX2015012922A (es) | Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular. | |
AR082340A1 (es) | Metodos y composiciones para la terapia del cancer de higado | |
MX2019012464A (es) | Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl. | |
MX359210B (es) | Composición de combinación de pac-1 y tamoxifeno. | |
MX369664B (es) | Composiciones de nanoparticulas inorganicas en combinacion con radiaciones ionizantes para tratar el cancer. | |
MX2015014599A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer. | |
IL271442A (en) | Preparations and methods for treating cancer with dengue virus and dendritic cells | |
MX2019013862A (es) | Terapia de combinacion. | |
PH12021550035A1 (en) | Combination therapy | |
IN2014MN01944A (es) | ||
MX2015006096A (es) | Leucocitos como celulas de administracion para imagen y terapia de enfermedad. | |
MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
GB2534478A (en) | Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10 | |
GB2528604A (en) | Modulation of asymmetric proliferation | |
PH12014501044B1 (en) | Methods for improved wound closure employing olivamine and human umbilical vien endothelial cells | |
MX2017013668A (es) | Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer. |